BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7479230)

  • 41. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.
    Williams SF; Ultmann JE; Gaynor E; Watson S
    Cancer Treat Rep; 1986 Aug; 70(8):1033-4. PubMed ID: 2425964
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Stahel RA; Jost LM; Honegger H; Betts E; Goebel ME; Nagler A
    J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen.
    Zuckerman KS; LoBuglio AF; Reeves JA
    J Clin Oncol; 1990 Feb; 8(2):248-56. PubMed ID: 2299368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current status of chemotherapy in the treatment of malignant lymphomas].
    Ohnoshi T; Hayashi K; Ueno K; Tada A; Murashima M; Mizuta J; Tagawa S; Kimura I
    Gan To Kagaku Ryoho; 1989 May; 16(5):1989-96. PubMed ID: 2658838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.
    Ahmed T; Cook P; Feldman E; Coombe N; Puccio C; Mittelman A; Chun H; Coleman M; Helson L
    Leukemia; 1994 Apr; 8(4):531-4. PubMed ID: 8152247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of combination chemotherapy with cis-dichlorodiammineplatinum on relapsed or therapy-resistant non-Hodgkin's lymphoma].
    Tsukasaki K; Ikeda S; Momita S; Nagai K; Murata K; Tokunaga S; Kohno T; Itoyama T; Toriya K; Kuriyama K
    Rinsho Ketsueki; 1988 May; 29(5):699-704. PubMed ID: 3216496
    [No Abstract]   [Full Text] [Related]  

  • 49. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress of radiation therapy in malignant lymphomas].
    Kaneta K; Nakazawa N; Kawabata K; Hashida J; Kawaguchi T; Yamashita T
    Gan No Rinsho; 1988 Apr; 34(5):555-64. PubMed ID: 3385921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hodgkin's disease and hypothermia: case report and review of the literature.
    Robin V; Lebacq J; Michaux L; Ferrant A
    Ann Hematol; 2002 Feb; 81(2):106-7. PubMed ID: 11907792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
    Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma--its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy].
    Tanosaki R; Okamoto S
    Rinsho Ketsueki; 1996 Jul; 37(7):591-7. PubMed ID: 8779778
    [No Abstract]   [Full Text] [Related]  

  • 56. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Medicinal therapy of malignant lymphomas].
    Aul C; Schroeder M; Giagounidis A
    Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    George B; Benson W; Hertzberg MS
    Bone Marrow Transplant; 2012 Jul; 47(7):1001-2. PubMed ID: 22002487
    [No Abstract]   [Full Text] [Related]  

  • 59. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
    Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
    Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stop-flow in mediastinum and thorax for resistant lymphoma.
    Guadagni S; Russo F; Abate G; Pozone T; Capannolo B; Marsili L; D'Alessandro V; Amicucci G; Aigner KR
    Hepatogastroenterology; 2000; 47(32):378-82. PubMed ID: 10791194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.